GO:0035589 G protein-coupled purinergic nucleotide receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035589 describes a biological process in which extracellular purine nucleotides such as ATP, ADP, UTP, or UDP bind to G protein-coupled P2Y receptors and trigger intracellular signaling that regulates downstream cellular responses.
• P2Y receptors are the molecular initiators of this pathway; they couple to Gq/11, Gi/o, or G12/13 proteins and modulate calcium, cAMP, and Rho-dependent effectors.
• The pathway is active in many tissues, including brain, kidney, liver, immune cells, and reproductive organs, where it controls inflammation, vascular tone, secretion, and cell migration.
• Purinergic GPCR signaling is implicated in Alzheimer's disease, neuropathic pain, pruritus, liver disease, and kidney disease, making it a broad therapeutic target.
• Key research tools include receptor agonists/antagonists, knockout and knock-in mouse models, live-cell calcium imaging, and CRISPR-based gene editing of P2Y receptor genes.
• Understanding GO:0035589 helps researchers connect extracellular nucleotide signals to specific disease mechanisms and to rational drug development.
Description
G protein-coupled purinergic nucleotide receptor signaling pathway (GO:0035589) is the biological process initiated when an extracellular purine nucleotide binds to a G protein-coupled receptor and culminates in regulation of a downstream cellular process. The receptors responsible are the P2Y family of G protein-coupled receptors, which respond to nucleotides such as ATP, ADP, UTP, and UDP and are widely expressed across mammalian tissues. This pathway is distinct from ionotropic P2X receptor signaling because it depends on heterotrimeric G proteins rather than direct ion channel opening. Because purinergic signals are released during cell stress, injury, and inflammation, this pathway acts as a rapid environmental sensor for many cell types. Researchers study GO:0035589 to understand how extracellular nucleotides shape microglial responses, vascular function, epithelial secretion, and immune cell behavior. The pathway is also a validated drug target: several P2Y receptor ligands are used clinically or are in development for thrombotic and inflammatory conditions. In the nervous system, P2Y12 receptor signaling is involved in neuropathic pain progression, while broader purinergic signaling contributes to Alzheimer's disease pathology. In peripheral organs, purinergic GPCR signaling participates in liver pathophysiology and kidney disease, linking nucleotide metabolism to organ dysfunction. This article summarizes the authoritative definition, core mechanism, key genes, disease relevance, and experimental methods for GO:0035589.
G protein-coupled purinergic nucleotide receptor signaling pathway At A Glance
| GO ID | GO:0035589 |
|---|---|
| GO term | G protein-coupled purinergic nucleotide receptor signaling pathway |
| Ontology | biological_process |
| Synonym | P2Y receptor signaling pathway |
| Definition | A G protein-coupled receptor signaling pathway initiated by an extracellular purine nucleotide binding to its receptor, and ending with the regulation of a downstream cellular process. |
| Major function | Transduces extracellular purine nucleotide signals into intracellular G protein-dependent responses. |
| Receptor family | P2Y G protein-coupled receptors. |
| Endogenous ligands | ATP, ADP, UTP, UDP, and related purine nucleotides. |
| G protein coupling | Gq/11, Gi/o, and G12/13 depending on receptor subtype. |
| Tissue distribution | Brain, kidney, liver, immune cells, reproductive tissues, and vasculature. |
What Is GO:0035589?
GO:0035589 is defined as a G protein-coupled receptor signaling pathway that begins with extracellular purine nucleotide binding to its receptor and ends with regulation of a downstream cellular process. In practice, this means a nucleotide such as ATP or ADP acts as a first messenger, activates a P2Y receptor on the cell surface, and causes the receptor to activate heterotrimeric G proteins. The activated G protein subunits then regulate enzymes or ion channels, producing second messengers such as inositol trisphosphate, diacylglycerol, or changes in cyclic AMP. The pathway is therefore a signal transduction cascade rather than a metabolic pathway, and its output depends on the receptor subtype, the G protein coupled, and the cell context.
Why Is G protein-coupled purinergic nucleotide receptor signaling pathway Important in Cell Biology?
GO:0035589 is important because it converts extracellular nucleotide signals into precise cellular responses and is involved in both normal physiology and multiple human diseases. Purinergic GPCR signaling controls microglial process extension after brain injury, contributes to neuropathic pain, and participates in Alzheimer's disease-related neuroinflammation. In peripheral organs, the pathway regulates liver pathophysiology and kidney disease progression, and it influences pruritus and spermatogenesis. Because P2Y receptors are druggable GPCRs, understanding this process supports development of selective agonists and antagonists for thrombosis, inflammation, and neurological disorders.
• Provides a mechanistic link between extracellular ATP/ADP/UTP/UDP and intracellular calcium, cAMP, and Rho signaling.
• Controls rapid microglial responses to local brain injury, a key innate immune function in the CNS.
• Is implicated in Alzheimer's disease through purinergic regulation of neuroinflammation and synaptic function.
• Contributes to neuropathic pain progression via P2Y12 receptor signaling.
• Regulates liver pathophysiology, including inflammation and fibrotic responses.
• Participates in kidney disease mechanisms such as glomerular and tubular injury.
• Modulates pruritus and sensory neuron excitability through P2 purinergic signaling.
• Influences spermatogenesis and reproductive function through purinergic pathways.
• Offers validated drug targets because P2Y receptors are GPCRs with known pharmacology.
• Enables CRISPR-based functional studies of receptor genes in disease models.
What Happens During G protein-coupled purinergic nucleotide receptor signaling pathway?
Nucleotide release and receptor binding
In simple terms: A cell releases ATP or a related nucleotide, and it lands on a P2Y receptor on another cell.
The pathway begins when extracellular purine nucleotides such as ATP, ADP, UTP, or UDP become available in the extracellular space and bind to a P2Y G protein-coupled receptor. Nucleotide release can occur during cell stress, injury, or regulated secretion, and the local nucleotide concentration determines receptor occupancy. Each P2Y receptor subtype has a distinct preference for specific nucleotides, which allows the pathway to encode different signals depending on which nucleotide is present.
G protein activation
In simple terms: The receptor switches on a G protein inside the cell.
Ligand-bound P2Y receptors act as guanine nucleotide exchange factors for heterotrimeric G proteins. Depending on the receptor subtype, the activated G alpha subunit can belong to the Gq/11, Gi/o, or G12/13 families. Gq/11 activation stimulates phospholipase C beta, Gi/o inhibits adenylyl cyclase, and G12/13 activates Rho guanine nucleotide exchange factors.
Second messenger generation
In simple terms: The G protein makes small messenger molecules that carry the signal forward.
Activated Gq/11 leads to phospholipase C beta-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate and diacylglycerol. Inositol trisphosphate triggers calcium release from intracellular stores, while diacylglycerol activates protein kinase C. Gi/o-coupled P2Y receptors reduce cyclic AMP levels, and G12/13-coupled receptors promote Rho-dependent cytoskeletal changes.
Downstream cellular responses
In simple terms: The signal changes what the cell does, such as moving, secreting, or changing gene expression.
The second messengers and effector proteins activated by P2Y receptors regulate diverse downstream processes, including cell migration, secretion, proliferation, and inflammatory mediator release. In microglia, purinergic GPCR signaling contributes to rapid process extension toward sites of brain injury. In the kidney and liver, these responses influence tubular transport, inflammation, and fibrotic remodeling.
Signal termination and desensitization
In simple terms: The cell shuts the signal off so it does not stay active forever.
P2Y receptor signaling is terminated by enzymatic degradation of extracellular nucleotides, receptor phosphorylation, and arrestin-mediated desensitization or internalization. These regulatory steps ensure that purinergic responses are transient and spatially restricted. Dysregulation of termination mechanisms can prolong signaling and contribute to pathological states such as chronic inflammation.
Key Genes Involved in GO:0035589 G protein-coupled purinergic nucleotide receptor signaling pathway
The genes most directly involved in GO:0035589 encode P2Y receptors and their downstream G protein and effector components.
| Gene | Major Role | Research Relevance |
|---|---|---|
| P2RY1 | Gq-coupled receptor for ADP and ATP | Vascular and platelet function studies |
| P2RY2 | Gq/Gi-coupled receptor for ATP and UTP | Epithelial secretion and inflammation research |
| P2RY4 | Gq-coupled receptor for UTP | Sensory and epithelial signaling studies |
| P2RY6 | Gq-coupled receptor for UDP | Immune and inflammatory response research |
| P2RY11 | Gq/Gs-coupled receptor for ATP | Neuroinflammation and immune cell studies |
| P2RY12 | Gi-coupled receptor for ADP | Microglial motility and neuropathic pain research |
| P2RY13 | Gi-coupled receptor for ADP | Microglial and CNS function studies |
| P2RY14 | Gi-coupled receptor for UDP-glucose | Innate immunity and epithelial studies |
| GNAQ | Gq alpha subunit | Core G protein mediator of P2Y signaling |
| GNAI1 | Gi alpha subunit | Inhibitory cAMP regulation in P2Y signaling |
| GNA12 | G12 alpha subunit | Rho-dependent P2Y signaling |
| PLCB1 | Phospholipase C beta 1 | Second messenger production downstream of Gq |
| PLCB2 | Phospholipase C beta 2 | Second messenger production in hematopoietic cells |
| PRKCA | Protein kinase C alpha | Diacylglycerol effector in P2Y signaling |
| ARRB1 | Beta-arrestin 1 | Receptor desensitization and internalization |
| ARRB2 | Beta-arrestin 2 | Receptor desensitization and signaling bias |
| ITPR1 | Inositol 1,4,5-trisphosphate receptor | Calcium release downstream of P2Y activation |
How Is G protein-coupled purinergic nucleotide receptor signaling pathway Regulated?
GO:0035589 is regulated at multiple levels. Extracellular nucleotide availability is controlled by ectonucleotidases such as CD39 and CD73, which degrade ATP and ADP and thereby limit receptor activation. Receptor-level regulation includes phosphorylation by G protein-coupled receptor kinases and binding of beta-arrestins, which desensitize and internalize P2Y receptors. G protein signaling is additionally modulated by regulators of G protein signaling proteins and by the specific G alpha subunit expressed in a given cell. In disease contexts, sustained purinergic tone can alter receptor expression and amplify inflammatory signaling, as seen in Alzheimer's disease and liver pathophysiology.
G protein-coupled purinergic nucleotide receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| P2RY12 | Neuropathic pain and microglial dysfunction | Knockout mouse with nerve injury model |
| P2RY12 | Alzheimer's disease neuroinflammation | Knock-in or knockout iPSC-derived microglia |
| P2RY2 | Epithelial secretion and inflammation | Overexpression cell model |
| P2RY6 | Inflammatory immune responses | Knockout macrophage model |
| P2RY14 | Innate immunity and epithelial defense | Point-mutation knock-in model |
Neurodegeneration and Alzheimer's disease
Purinergic signaling, including G protein-coupled P2Y receptor pathways, is implicated in Alzheimer's disease through effects on neuroinflammation, microglial activation, and synaptic dysfunction. P2Y12 receptor signaling is specifically involved in microglial responses and in the progression of neuropathic pain, linking this pathway to chronic pain states. These findings support targeting purinergic GPCRs for neurological disease research.
Liver and kidney disease
Purinergic signaling participates in liver pathophysiology, where nucleotide-mediated GPCR activation influences inflammation, vascular tone, and fibrotic responses. In the kidney, purinergic pathways contribute to glomerular and tubular injury and to progression of kidney disease. These organ systems provide clear contexts for studying GO:0035589 in disease models.
Pruritus and sensory disorders
P2 purinergic signaling is involved in pruritus, where nucleotide-activated receptors modulate sensory neuron activity and itch transmission. This connects GO:0035589 to somatosensory disorders and to potential antipruritic drug development.
Reproductive biology
Purinergic signaling has been described in spermatogenesis, indicating a role for nucleotide-GPCR pathways in male reproductive function. This broadens the physiological relevance of GO:0035589 beyond neurological and metabolic disease.
From G protein-coupled purinergic nucleotide receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is P2RY12 required for microglial process extension after injury? | P2RY12 knockout mouse or CRISPR knockout microglial cell line |
| Does a specific P2Y receptor variant alter ligand sensitivity? | Point-mutation knock-in cell model |
| Can a tagged P2Y receptor be used to track localization? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of P2RY2 increase secretion? | Overexpression cell model |
| Which downstream effectors mediate P2Y signaling? | CRISPR library screening for pathway modifiers |
| Does P2Y receptor signaling contribute to pruritus? | Knockout mouse and sensory neuron assays |
How to Study the G protein-coupled purinergic nucleotide receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular calcium changes | Gq-coupled P2Y receptor activation |
| cAMP assay | Cyclic AMP levels | Gi/o-coupled P2Y receptor activity |
| Rho activation assay | Rho GTPase activity | G12/13-coupled P2Y signaling |
| CRISPR knockout | Loss of receptor function | Causal testing of P2Y receptor genes |
| Live-cell imaging | Cell migration and morphology | Microglial injury responses |
| RNA sequencing | Gene expression profiles | Pathway component discovery |
| Pharmacological profiling | Agonist/antagonist potency | Receptor subtype selectivity |
| Bioinformatic pathway analysis | Enrichment of purinergic genes | Disease dataset interpretation |
Calcium imaging and second messenger assays
Because P2Y receptors often couple to Gq/11, intracellular calcium mobilization is a standard readout for GO:0035589 activity. Fluorescent calcium indicators and plate-based assays allow measurement of receptor activation by nucleotides or selective agonists. cAMP assays are used for Gi/o-coupled P2Y receptors, and Rho activation assays for G12/13-coupled subtypes.
Genetic and pharmacological perturbation
Knockout, knockdown, or CRISPR-mediated editing of P2Y receptor genes provides causal tests of pathway function. Selective agonists and antagonists, such as those developed for P2Y12, allow acute pharmacological dissection of the pathway. Combining genetic and pharmacological tools helps distinguish receptor-specific effects from global purinergic tone.
Live-cell imaging in disease models
Live imaging of microglia in brain slices has been used to show that ATP mediates rapid microglial responses to local injury, a process linked to purinergic GPCR signaling. Similar imaging approaches can be applied to study P2Y receptor-dependent migration and morphological changes. These methods connect molecular pathway activity to tissue-level behavior.
Transcriptomic and bioinformatic analysis
RNA sequencing and bioinformatic pathway analysis can identify which P2Y receptors and downstream effectors are expressed in a given tissue or disease state. Comparing expression profiles across conditions helps prioritize candidate genes for functional studies. Such analyses are often the first step before designing CRISPR models of GO:0035589 components.
How CRISPR Can Be Used to Study GO:0035589 G protein-coupled purinergic nucleotide receptor signaling pathway
Knockout
CRISPR knockout of P2Y receptor genes such as P2RY12 or P2RY2 removes the initiating receptor and allows researchers to test whether a cellular response depends on GO:0035589. Knockout models are useful for validating receptor-specific contributions to microglial motility, inflammation, or secretion. They also provide clean backgrounds for re-expression or rescue experiments.
Point Mutation
Point mutations can be introduced into P2Y receptor genes to alter ligand binding, G protein coupling, or phosphorylation sites. Such models help dissect which residues are required for pathway activation versus desensitization. They are particularly valuable for studying disease-associated variants of purinergic receptors.
Knock-in
Knock-in of tags or reporter sequences into endogenous P2Y receptor loci enables tracking of receptor expression and localization without overexpression artifacts. Tagged knock-in models can be used for imaging receptor trafficking after nucleotide stimulation. Knock-in of humanized receptor variants can also support drug discovery studies.
Overexpression
Overexpression of a P2Y receptor or a downstream effector can amplify pathway output and make weak signals easier to measure. This approach is useful for screening agonists and antagonists in cell-based assays. However, overexpression results should be interpreted with caution because receptor density can alter signaling bias.
How EDITGENE Supports G protein-coupled purinergic nucleotide receptor signaling pathway Research
Researchers studying G protein-coupled purinergic nucleotide receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in a specific cellular response or disease phenotype. EDITGENE provides CRISPR-based cell model services that enable precise knockout, point mutation, knock-in, and overexpression of P2Y receptor genes and their downstream effectors. These models support functional validation of GO:0035589 components in relevant cell types and disease contexts.
Contact EDITGENE today to design your custom CRISPR model for G protein-coupled purinergic nucleotide receptor signaling pathway research.
Frequently Asked Questions About G protein-coupled purinergic nucleotide receptor signaling pathway
What is GO:0035589?
GO:0035589 is the Gene Ontology term for G protein-coupled purinergic nucleotide receptor signaling pathway, a process in which extracellular purine nucleotides bind P2Y receptors and activate G protein-dependent cellular responses.
What is the G protein-coupled purinergic nucleotide receptor signaling pathway?
It is a signal transduction pathway initiated by nucleotide binding to P2Y G protein-coupled receptors, leading to regulation of downstream cellular processes.
What genes are involved in G protein-coupled purinergic nucleotide receptor signaling pathway?
Key genes include P2RY1, P2RY2, P2RY4, P2RY6, P2RY11, P2RY12, P2RY13, P2RY14, and G protein subunits such as GNAQ, GNAI1, and GNA12.
Which receptors mediate GO:0035589?
The P2Y family of G protein-coupled receptors mediates this pathway and responds to ATP, ADP, UTP, and UDP.
What diseases are linked to purinergic GPCR signaling?
It has been linked to Alzheimer's disease, neuropathic pain, pruritus, liver disease, and kidney disease.
How is P2Y receptor signaling terminated?
It is terminated by ectonucleotidase-mediated nucleotide degradation, receptor phosphorylation, and beta-arrestin-mediated desensitization.
What methods are used to study GO:0035589?
Common methods include calcium imaging, cAMP assays, CRISPR knockout, live-cell imaging, RNA sequencing, and pharmacological profiling.
Is P2Y12 receptor involved in neuropathic pain?
Yes, P2Y12 receptor signaling has been implicated in the progression of neuropathic pain.
Does purinergic signaling play a role in Alzheimer's disease?
Yes, purinergic signaling, including GPCR-mediated pathways, is involved in Alzheimer's disease-related neuroinflammation and pathology.
Can CRISPR be used to study purinergic receptor genes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study P2Y receptor function.
Conclusion
GO:0035589, the G protein-coupled purinergic nucleotide receptor signaling pathway, is a central mechanism by which extracellular nucleotides control cell behavior through P2Y receptors and heterotrimeric G proteins. Its involvement in microglial injury responses, neuropathic pain, Alzheimer's disease, liver and kidney disease, pruritus, and spermatogenesis makes it a high-value research area. CRISPR-based cell models provide a precise way to dissect receptor-specific and effector-specific contributions to this pathway. Continued functional studies will clarify how purinergic GPCR signaling can be targeted therapeutically across diverse diseases.
References
- 1. Mundt N et al.. 2022. Purinergic Signaling in Spermatogenesis.. Front Endocrinol (Lausanne) 13:867011 PMID: 35480481
- 2. Davalos D et al.. 2005. ATP mediates rapid microglial response to local brain injury in vivo.. Nat Neurosci 8(6):752-8 PMID: 15895084
- 3. Erb L et al.. 2019. Purinergic signaling in Alzheimer's disease.. Brain Res Bull 151:25-37 PMID: 30472151
- 4. Jain S et al.. 2021. Purinergic Signaling in Liver Pathophysiology.. Front Endocrinol (Lausanne) 12:718429 PMID: 34456873
- 5. von Kügelgen I. 2019. Pharmacology of P2Y receptors.. Brain Res Bull 151:12-24 PMID: 30922852
- 6. Liu S et al.. 2025. P2 purinergic signaling and pruritus.. Neuropharmacology 275:110497 PMID: 40334932
- 7. Ming LG et al.. 2023. G protein-coupled P2Y12 receptor is involved in the progression of neuropathic pain.. Biomed Pharmacother 162:114713 PMID: 37084563
- 8. Menzies RI et al.. 2017. Purinergic signaling in kidney disease.. Kidney Int 91(2):315-323 PMID: 27780585
